Trial Profile

A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 19 Jan 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Loncastuximab tesirine (Primary)
Indications B-cell lymphoma; Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Acronyms LOTIS 2
Sponsors ADC Therapeutics

Most Recent Events

12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
19 Oct 2023 Results assessing the prognosis of PET/CT-biomarkers in patients treated with loncastuximab tesirine published in the Clinical Cancer Research
12 Sep 2023 Results presented at the 2023 American College of Clinical Pharmacology Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com